Jennifer Litton discusses results of the NEOTALA trial suggesting patients with germline BRCA1/2-mutant, HER2-negative, early breast cancer may benefit from neoadjuvant treatment with talazoparib (4:56).
18-06-2021 | ASCO 2021 | Conference coverage | Video